◎ Sugi Atlas

Atlas / Drug / Betamethasone

Betamethasone

drug
On this page

Also known as BetametasonaBetnelanBetasolanCelestoneFlubenisoloneLotrisoneNSC-39470RinderonSCH 4831SCH-4831TaclonexVISUBETABetamethazoneSID90341476SID46500420SID26757820SID144205668SID56320847SID144211772

Summary

Betamethasone (CHEMBL632) is an approved small-molecule anti-inflammatory drug (ATC D07AC01) targeting NR3C1; indicated across 33 conditions including eye disorder and obstructive lung disease.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: D07AC01 (+10 more)
  • Targets: 1 (NR3C1)
  • Indications: 33 conditions
  • Clinical trials: 2,740
  • Chemistry: 392.5 Da · C22H29FO5

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL632
NameBetamethasone
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID9782
ChEBICHEBI:3077
ATCD07AC01, D07XC01, H02AB01, S02BA07, S01CB04, S03BA03, R03BA04, S01BA06, A07EA04, R01AD06, C05AA05
Molecular formulaC22H29FO5
Molecular weight392.5
InChIKeyUREBDLICKHMUKA-DVTGEIKXSA-N

SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C

IUPAC name: (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

Pharmacological roles (ChEBI): anti-inflammatory drug, anti-asthmatic agent, immunosuppressive agent.

Also known as: Betametasona, Betamethasone, Betnelan, Betasolan, Celestone, Flubenisolone, Lotrisone, NSC-39470, Rinderon, SCH 4831, SCH-4831, Taclonex

Patent coverage: 20,074 distinct patent families (76,849 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
NR3C1Glucocorticoid receptorFull agonist8.110.9%P04150

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Androgen receptor, Glucocorticoid receptor, Progesterone receptor.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
NR3C18.45Ki3.52nMCHEMBL_ACT_7617999
NR3C18.11IC507.74nMCHEMBL_ACT_7617998
AR5.32AC504824nMCHEMBL_ACT_25203872

Target pathways

Aggregated over 1 target gene(s): NR3C1.

Top Reactome pathways

8 total, by targets touching each:

PathwayTargetsGenes
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand1NR3C1
Nuclear Receptor transcription pathway1NR3C1
SUMOylation of intracellular receptors1NR3C1
PTK6 Expression1NR3C1
Regulation of RUNX2 expression and activity1NR3C1
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes1NR3C1
Potential therapeutics for SARS1NR3C1
Regulation of NPAS4 gene transcription1NR3C1

Dominant GO biological processes

GO termTargets
negative regulation of transcription by RNA polymerase II1
regulation of gluconeogenesis1
chromatin organization1
regulation of DNA-templated transcription1
regulation of transcription by RNA polymerase II1
apoptotic process1
chromosome segregation1
signal transduction1
glucocorticoid metabolic process1
response to wounding1
gene expression1
microglia differentiation1
adrenal gland development1
nuclear receptor-mediated steroid hormone signaling pathway1
regulation of glucocorticoid biosynthetic process1

Indications & clinical

Indications

33 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
eye disorder4MONDO:0005328EFO:0005752
obstructive lung disease4MONDO:0002267HP:0006536
hemorrhoid4MONDO:0004872EFO:0009552
psoriasis3MONDO:0005083EFO:0000676
carpal tunnel syndrome3MONDO:0007275EFO:0004143
allergic rhinitis3MONDO:0011786EFO:0005854
acute respiratory distress syndrome3MONDO:0006502EFO:1000637
lichen planus, oral3MONDO:0043923EFO:0008517
pharyngitis3MONDO:0002258MONDO:0002258
orbital pseudotumor3MONDO:0004769EFO:1001077
allergic disease3MONDO:0005271MONDO:0005271
gout3MONDO:0005393EFO:0004274
atopic eczema2MONDO:0004980EFO:0000274
newborn respiratory distress syndrome2MONDO:0700081EFO:1000644
retinal vein occlusion2MONDO:0006951EFO:1001157
melanoma2MONDO:0005105EFO:0000756
sciatica2MONDO:0024333HP:0011868
bronchiolitis2MONDO:0002465HP:0011950
dry eye syndrome2MONDO:0006733EFO:1000906
glaucoma2MONDO:0005041MONDO:0005041
adenoma1MONDO:0004972EFO:0000232
hypospadias0MONDO:0005345EFO:0004209

11 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2,740.

Phase distribution

(phase/status distribution below is over 1,600 sampled trials of the 2,740 total).

PhaseTrials
PHASE3529
PHASE2446
PHASE4440
PHASE1/PHASE2114
PHASE2/PHASE371

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01553214PHASE4RECRUITINGImproving White Blood Cell Collection From Healthy Donors
NCT03829371PHASE4ACTIVE_NOT_RECRUITINGSTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
NCT04025840PHASE4ACTIVE_NOT_RECRUITINGPerioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery
NCT04150614PHASE4RECRUITINGBMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
NCT04182997PHASE4RECRUITINGSubjective Intraoperative Use of Epidural Steroid Administration Following Discectomy
NCT04205916PHASE4RECRUITINGA Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery
NCT04432012PHASE4RECRUITINGA Study to Compare Different Ways of Steroid Administration After Total Knee Implantation
NCT04432259PHASE4NOT_YET_RECRUITINGOral Dexamethasone as an Intervention for Postoperative Pain and Nausea Management in Total Knee Arthroplasty
NCT04507412PHASE4RECRUITINGIntravenous Dexamethasone Administration in Patients Undergoing Total Shoulder Arthroplasty
NCT04545242PHASE4RECRUITINGEfficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions
NCT04826237PHASE4RECRUITINGOral Statins and Protection From Hearing Loss
NCT05072262PHASE4RECRUITINGDSAEK/DMEK and Cystoid Macular Edema - the Role for Topical NSAIDs (Nepafenac) (DMEC)
NCT05114096PHASE4RECRUITINGSingle Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)
NCT05191706PHASE4RECRUITINGEvaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
NCT05435547PHASE4RECRUITINGPreoperative Corticosteroids in Autoimmune Thyroid Disease
NCT05488847PHASE4ACTIVE_NOT_RECRUITINGOpioid-Free Pain Protocol After Shoulder Arthroplasty
NCT05518383PHASE4RECRUITINGB-cell Mature Non-Hodgkin’s Lymphoma Treatment Protocol in Children and Adolescents 2021
NCT05522465PHASE4RECRUITINGShort-course High-dose Prednisone and Dexamethasone in Children With ITP
NCT05561725PHASE4RECRUITINGPerioperative Steroid Dosing on the APR in AIS
NCT05716945PHASE4RECRUITINGThe OPTIMISE Study
NCT05721027PHASE4RECRUITINGIbuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.
NCT05731960PHASE4RECRUITINGEvaluating the Effect of Intravenous Dexamethasone on the Duration of Spinal Anesthesia After Cesarean Delivery
NCT05824832PHASE4RECRUITINGBuprenorphine, Clonidine, and Dexamethasone on Duration of Brachial Plexus Blocks for Upper Extremity Surgery
NCT05936528PHASE4NOT_YET_RECRUITINGLactoferrin Use in ICU Patients
NCT06006624PHASE4ENROLLING_BY_INVITATIONExparel vs Block for ACL Reconstruction
NCT06023043PHASE4NOT_YET_RECRUITINGPostoperative Steroid Use in Adolescent Idiopathic Scoliosis and Neuromuscular Scoliosis Patients
NCT06044480PHASE4NOT_YET_RECRUITINGEffect of Dexamethason on Postimplantation Syndrome After EVAR
NCT06118710PHASE4RECRUITINGEvaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment
NCT06160180PHASE4NOT_YET_RECRUITINGComparative Assessment of Preoperative Versus Postoperative Submucosal Dexamethasone on Postoperative Complications Following Surgical Extraction of Mandibular Third Molar: Randomized Controlled Trial
NCT06268704PHASE4RECRUITINGParticulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection
NCT06289673PHASE4RECRUITINGIdentification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
NCT06367855PHASE4RECRUITINGEfficacy and Safety of Preemptive Intravenous Dexamethasone in MIS-TLIF
NCT06404541PHASE4ACTIVE_NOT_RECRUITINGA Comparative Study Between Preservative With Benzalkonium Chloride vs Preservative Free Eye Drops on the Ocular Surface
NCT06408974PHASE4NOT_YET_RECRUITINGComparison Between Ketamine Intrathecal and iv Dexamethasone for Post Cesarean Analgesia
NCT06409702PHASE4RECRUITINGTreatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
NCT06465992PHASE4ENROLLING_BY_INVITATIONLiposomal Bupivacaine With Dexamethasone for Foot Surgery
NCT06575010PHASE4ENROLLING_BY_INVITATIONExparel v Dexamethasone in RCR
NCT06603662PHASE4RECRUITINGSystemic Oral Glucocorticoids for the Treatment of Acute Osteoarthritis Pain in the Emergency Department
NCT06624436PHASE4RECRUITINGImmunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia
NCT06685991PHASE4NOT_YET_RECRUITINGEffect of Timing of Dexamethasone During Induction on Postoperative Outcomes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

173 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
FULVESTRANTChEMBL + PubChemPhase 4 (approved)NR3C1
PODOFILOXChEMBL + PubChemPhase 4 (approved)NR3C1
REGORAFENIBChEMBL + PubChemPhase 4 (approved)NR3C1
ACENOCOUMAROLChEMBLPhase 4 (approved)NR3C1
ALCLOMETASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
AMCINONIDEChEMBLPhase 4 (approved)NR3C1
AMIODARONEChEMBLPhase 4 (approved)NR3C1
APREPITANTChEMBLPhase 4 (approved)NR3C1
AURANOFINChEMBLPhase 4 (approved)NR3C1
BAZEDOXIFENEChEMBLPhase 4 (approved)NR3C1
BECLOMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BENZBROMARONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE PHOSPHORIC ACIDChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE VALERATEChEMBLPhase 4 (approved)NR3C1
BUDESONIDEChEMBLPhase 4 (approved)NR3C1
BUTOCONAZOLEChEMBLPhase 4 (approved)NR3C1
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)NR3C1
CANRENONEChEMBLPhase 4 (approved)NR3C1
CHLORMADINONEChEMBLPhase 4 (approved)NR3C1
CICLESONIDEChEMBLPhase 4 (approved)NR3C1
CLOBETASOL PROPIONATEChEMBLPhase 4 (approved)NR3C1
CLOFAZIMINEChEMBLPhase 4 (approved)NR3C1
CLOTRIMAZOLEChEMBLPhase 4 (approved)NR3C1
CORTISONEChEMBLPhase 4 (approved)NR3C1
DANAZOLChEMBLPhase 4 (approved)NR3C1
DAUNORUBICINChEMBLPhase 4 (approved)NR3C1
DEFLAZACORTChEMBLPhase 4 (approved)NR3C1
DESOGESTRELChEMBLPhase 4 (approved)NR3C1
DESONIDEChEMBLPhase 4 (approved)NR3C1
DESOXIMETASONEChEMBLPhase 4 (approved)NR3C1
DESOXYCORTICOSTERONE PIVALATEChEMBLPhase 4 (approved)NR3C1
DEXAMETHASONEChEMBLPhase 4 (approved)NR3C1
DEXTROTHYROXINEChEMBLPhase 4 (approved)NR3C1
DIENESTROLChEMBLPhase 4 (approved)NR3C1
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)NR3C1
DIFLORASONE DIACETATEChEMBLPhase 4 (approved)NR3C1
DOXORUBICINChEMBLPhase 4 (approved)NR3C1
DROSPIRENONEChEMBLPhase 4 (approved)NR3C1
ECONAZOLEChEMBLPhase 4 (approved)NR3C1
EFAVIRENZChEMBLPhase 4 (approved)NR3C1
ENZALUTAMIDEChEMBLPhase 4 (approved)NR3C1
EPLERENONEChEMBLPhase 4 (approved)NR3C1
ESTRADIOLChEMBLPhase 4 (approved)NR3C1
ESTRIOLChEMBLPhase 4 (approved)NR3C1
ETHINYL ESTRADIOLChEMBLPhase 4 (approved)NR3C1
EXEMESTANEChEMBLPhase 4 (approved)NR3C1
FELODIPINEChEMBLPhase 4 (approved)NR3C1
FLUDROCORTISONEChEMBLPhase 4 (approved)NR3C1
FLUNISOLIDEChEMBLPhase 4 (approved)NR3C1
FLUOCINOLONE ACETONIDEChEMBLPhase 4 (approved)NR3C1
FLUOCINONIDEChEMBLPhase 4 (approved)NR3C1
FLUOROMETHOLONEChEMBLPhase 4 (approved)NR3C1
FLUOXYMESTERONEChEMBLPhase 4 (approved)NR3C1
FLURANDRENOLIDEChEMBLPhase 4 (approved)NR3C1
FLUTICASONE FUROATEChEMBLPhase 4 (approved)NR3C1
FLUTICASONE PROPIONATEChEMBLPhase 4 (approved)NR3C1
GLUCAGONChEMBLPhase 4 (approved)NR3C1
HALCINONIDEChEMBLPhase 4 (approved)NR3C1
HYDROCORTISONEChEMBLPhase 4 (approved)NR3C1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot